Clincosm LogoSign in Get a demo

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

Sponsor
Shionogi (Industry)
Overall Status
Completed
CT.gov ID
NCT01126970
Collaborator
(none)
486
Enrollment
25
Locations
4
Arms
10.1
Duration (Months)
19.4
Patients Per Site
1.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the steady-state trough concentrations of velneperit (S-2367), velneperit (S-2367) tert-butyl OH, and velneperit (S-2367) tert-butyl OH-O glucuronide following 400 mg of velneperit (S-2367) three times per day and 120 mg of orlistat, either combined or separate.

Condition or Disease Intervention/Treatment Phase
  • Drug: Velneperit 400 mg
  • Drug: Orlistat 120 mg
  • Drug: Orlistat Placebo
  • Drug: Velneperit Placebo
  • Other: Reduced Calorie Diet
 Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
486 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Double-Blind, Multi-Center, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of 400 mg of Velneperit (S-2367) and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day With a Reduced Calorie Diet (RCD) in Obese Subjects
Study Start Date :
Apr 1, 2010
Actual Primary Completion Date :
Jan 1, 2011
Actual Study Completion Date :
Feb 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebos.

Velneperit Placebo q.d.+ Orlistat Placebo t.i.d.

Drug: Orlistat Placebo
Orlistat Placebo t.i.d.

Drug: Velneperit Placebo
Velneperit Placebo q.d

Other: Reduced Calorie Diet
Reduced calorie diet
Experimental: Velneperit 400 mg

Velneperit 400 mg q.d.

Drug: Velneperit 400 mg
Velneperit 400 mg q.d.
Other Names:
  • S-2367

    • Drug: Orlistat Placebo
    Orlistat Placebo t.i.d.

    Other: Reduced Calorie Diet
    Reduced calorie diet
    Active Comparator: Orlistat 120 mg

    Orlistat 120 mg t.i.d.

    Drug: Orlistat 120 mg
    Orlistat 120 mg t.i.d
    Other Names:
  • Xenical

    • Drug: Velneperit Placebo
    Velneperit Placebo q.d

    Other: Reduced Calorie Diet
    Reduced calorie diet
    Experimental: Velneperit 400 mg + Orlistat 120 mg

    Velneperit 400 mg q.d.and Orlistat 120 mg t.i.d

    Drug: Velneperit 400 mg
    Velneperit 400 mg q.d.
    Other Names:
  • S-2367

    • Drug: Orlistat 120 mg
    Orlistat 120 mg t.i.d
    Other Names:
  • Xenical

    • Other: Reduced Calorie Diet
    Reduced calorie diet

    Outcome Measures

    Primary Outcome Measures

    1. The primary efficacy endpoint was the change from baseline in body weight (kg) over the 168-day (24-week) double-blind treatment period, where baseline body weight was defined as the last measurement prior to randomization [168 days (24 weeks)]

      Change in body weight from baseline to 24 weeks

    Secondary Outcome Measures

    1. Efficacy analysis: The proportion of subjects with (a) a 5% decrease in body weight at Visit 7 and Visit 10 and (b) percent change in body weight from baseline to each study visit was summarized by treatment group [change from baseline to each study visit]

      Percentage of subjects who achieve a 5% decrease in body weight

    2. Efficacy analysis: The change in waist & hip circumference (cm) from baseline to each study visit was summarized by treatment group [Change from baseline to each study visit]

      Change in physical measurement from baseline

    3. Efficacy analysis: The proportion of subjects with a decrease equal to or greater than 1 BMI unit at Visit 7 and Visit 10 was summarized by treatment group [Baseline to Visits 7 and 10]

      The proportion of subjects with decreases in BMI of 1 unit

    4. Safety analysis: (a) Treatment-emergent adverse events and (b) monitoring clinical laboratory evaluations, vital signs, 12-lead electrocardiograms, and physical examinations [Baseline to each visit and to Week 24]

      Change from baseline to each visit and to Week 24

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Males and females between 18 and 65 years of age at the time of informed consent

    • Body mass index (BMI) of 30.0 to 45.0 kg/m2 inclusive. BMI for study inclusion must be obtained from the Interactive Voice Response System/Web Response System (IVRS/WRS). (Visit 1 body weight and height obtained prior to the single-blind period will be used by the IVRS/WRS in the calculation.)

    • Weight that has not fluctuated by more than 3% for the 90 days prior to Visit 1

    • Non-smoker and no use of tobacco or nicotine products for at least 1 year prior to Visit 1

    • Normotensive or acceptable level of hypertension, defined as systolic <160 and diastolic <95 mmHg

    • No clinically significant laboratory abnormalities

    • Negative urine drug screen for drugs of abuse

    • No clinically significant findings on medical history, physical examination, and electrocardiogram (ECG) and no known history of clinically significant ECG abnormalities

    • Negative serum pregnancy test in women of child-bearing potential (Females must be at least one year post-partum.)

    • Males either should remain abstinent, be sterile or agree to use an approved method of contraception (which for males includes use of a condom with spermicide) Visit 1 through 12 weeks following the last dose, in addition to having a female partner use an effective form of contraception as noted below

    • All female subjects must be non-pregnant (confirmed by a negative serum pregnancy test), have no plans of becoming pregnant during the study, and must be at least one year post-partum, non-lactating, postmenopausal, (defined as cessation of regular menstrual periods for at least one year and confirmed by a follicle-stimulating hormone test), or surgically sterile by hysterectomy and/or bilateral oophorectomy or tubal ligation. Females of child-bearing potential must agree to use acceptable forms of birth control including oral, implantable or transdermal contraceptives; or use of one of the following double-barrier methods: intrauterine device with spermicide, diaphragm with spermicide, cervical cap with spermicide, female condom with spermicide, or a male condom with spermicide by the male sexual partner

    • Able to comply with all required study procedures and schedule

    • Able to speak and read English

    • Signed and dated informed consent form prior to any study-related procedures

    Exclusion Criteria:

    • Obesity of known endocrine or genetic origin (eg, hypothyroidism, Cushing's syndrome or diagnosed polycystic ovarian syndrome) meeting one of the following conditions:

    • Menstrual irregularity due to oligo- or anovulation

    • Evidence of hyperandrogenism, whether clinical (hirsutism, acne, or male pattern balding) or biochemical (high serum androgen concentrations)

    • Exclusion of other causes of hyperandrogenism and menstrual irregularity, such as congenital adrenal hyperplasia, androgen-secreting tumors, and hyperprolactinemia]

    • History of malignancy within the previous 5 years with the exception of non-melanoma skin cancer or surgically cured cervical cancer

    • Human immunodeficiency virus (HIV) identified by history or previous HIV test

    • Any serious medical condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study including any clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs

    • Known history or evidence of a psychiatric disorder that in the opinion of the investigator would preclude the subject from participating in the trial. Stable or controlled anxiety or depression are permitted. Treatment with an antidepressant or anxiolytic drug is permitted if in accordance with Appendix 4. Subjects with a score of 11 or higher on the depression portion of the Hospital Anxiety and Depression Scale are excluded.

    • Subjects with pancreatitis or chronic pancreatic inflammation

    • History of Type 1 or Type 2 diabetes mellitus as defined by HbA1c > 6.5% or blood glucose values of > 126 mg/dl or treated Type 2 diabetes mellitus

    • Any weight gain during the single-blind lead-in period (Visit 1 and Visit 3)

    • History of surgical or device (eg, gastric bypass) intervention for obesity surgery, stomach banding surgery, or any other surgical procedure(s) that attempt to promote/aid weight loss. Note: Liposuction will be allowed if done more than 90 days prior to screening

    • History of alcoholism or drug addiction/substance abuse within 1 year of Visit 1. Note: No alcohol consumption is permitted within 48 hours prior to blood collections for analysis of lipid profiles.

    • Abnormal thyroid stimulating hormone level at screening

    • Subjects with hypothyroidism

    • Subjects with genetic hematologic disease or trait with or without manifestation of disease.

    • Use of chronic medications/products within 90 days prior to Visit 1 or during the study that are known to cause weight gain. Investigators will discuss with the Sponsor's Medical Monitor any concomitant medications about which they are uncertain.

    • Use of systemic corticosteroids or Depo Provera®

    • History of fenfluramine or dexfenfluramine (Fen-Phen) administration (except with a prior documented echocardiogram showing no valvular abnormalities.)

    • History of participation in any weight loss program within 90 days prior to Visit 1

    • Participation in any weight loss medication/product study in which receipt of weight loss medication/product occurred within 90 days prior to Visit 1

    • Use of any prescription or nonprescription over the counter medication/product or herbal/phytotherapeutic/plant-derived medications/products for weight loss, appetite suppression, weight control or treat obesity (includes investigational products) within 90 days prior to Visit 1 or during the study

    • Subjects with cholestasis or chronic malabsorption

    • Donation of blood or blood products 90 days prior to Visit 1 or during the study

    • Exposure to an investigative medication within the past 30 days or 5 half-lives, whichever is longer or concurrent participation in any clinical trial

    • Previous velneperit (S-2367) or other neuropeptide Y (NPY) Y5 agonist or antagonist use

    • Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study

    • Positive Hepatitis B or C serology

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Santa Rosa California United States
    2 Waterbury Connecticut United States
    3 Clearwater Florida United States
    4 Jacksonville Florida United States
    5 Ocala Florida United States
    6 Ponte Vedra Florida United States
    7 Augusta Georgia United States
    8 Louisville Kentucky United States
    9 Boston Massachusetts United States
    10 Milford Massachusetts United States
    11 North Dartmouth Massachusetts United States
    12 Saint Louis Missouri United States
    13 Lincoln Nebraska United States
    14 Albuquerque New Mexico United States
    15 Manlius New York United States
    16 Rochester New York United States
    17 Cary North Carolina United States
    18 Raleigh North Carolina United States
    19 Cleveland Ohio United States
    20 Columbus Ohio United States
    21 Greenville South Carolina United States
    22 Nashville Tennessee United States
    23 New Braunfels Texas United States
    24 Renton Washington United States
    25 Wauwatosa Wisconsin United States

    Sponsors and Collaborators

    • Shionogi

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Shionogi
    ClinicalTrials.gov Identifier:
    NCT01126970
    Other Study ID Numbers:
    • 1002A2828
    First Posted:
    May 20, 2010
    Last Update Posted:
    May 9, 2018
    Last Verified:
    May 1, 2018
    Keywords provided by Shionogi
    reduced calorie diet
    orlistat
    velneperit
    Additional relevant MeSH terms:
    Orlistat

    Study Results

    No Results Posted as of May 9, 2018